BTX

BlackRock Technology and Private Equity Term Trust

Fundamental data last updated:October 2, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NYSE

County of HQ

US

Next Earnings Date

Not Scheduled

Business Summary

BlackRock Innovation and Growth Trust (the Trust) is a newly-organized, non-diversified, closed-end management investment company with no operating history. The Trusts investment objectives are to provide total return and income through a combination of current income, current gains and long-term capital appreciation. There can be no assurance that the Trusts investment objectives will be achieved or that the Trusts investment program will be successful The Trust will invest primarily in equity securities issued by mid- and small-capitalization companies that the Trusts adviser believes have above-average earnings growth potential. In selecting investments for the Trust, the Trusts adviser focuses on mid- and small-capitalization growth companies that are innovative. These are companies that have introduced, or are seeking to introduce, a new product or service that potentially changes the marketplace.

 


VALUATION

P/E

55.39

Market Cap ($M USD)

$1.07B

Forward P/E

N/A

PEG

N/A

PRICE TO SALES

26.27

PRICE TO BOOK

2.16

EV / EBITDA

0.00

5-Year Average P/E

Free Cash Flow Yield

82.11%

DCF Value

$0.00

Graham Number

$3.97

Price to FCF

1.22

EV to FCF

1.22

Earnings Yield

1.81%

FCF Yield

82.11%

DIVIDEND

Yield

8.05%

Annual Payout

$0.74

Payout Ratio

429.62%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

$0.17

Next Year EPS Growth Estimate

N/A

Next Year Revenue Growth Estimate

N/A

Return on Equity (ROE)

2.64%

FREE CASH FLOW

Operating Margin

87.75%

Debt-to-Equity

0.00

Piotroski F-Score

N/A

Altman Z-Score

N/A

Return on Invested Capital (ROIC)

3.85%

Current Ratio

0.13

Quick Ratio

0.13

Net Debt to EBITDA

0.00

Interest Coverage

2313.25

Gross Profit margin

100.00%

FCF PER SHARE

$4.07

REVENUE PER SHARE

$0.19

Gainseekers Quantitative Analysis

Summary

The market seems to have misjudged BTX’s valuation, with its snapshot price trading significantly below its DCF value. The Price/Book ratio of 1.92 suggests a reasonable valuation, yet the Price/Earnings ratio of 49.28 indicates expectations of high growth. However, the earnings yield of just 2.03% raises questions about the stock’s attractiveness compared to safer investments. The absence of a Forward P/E and Altman Z-score leaves investors in the dark about future growth and financial stability, hinting at potential risks.

AI Exposure / Tech Reliance

Operating in the biotechnology sector, BTX is well-positioned to leverage AI advancements for drug discovery and personalized medicine. The industry's inherent focus on innovation aligns with modern tech shifts, offering resilience against technological disruptions. However, execution will be key in capitalizing on these opportunities.

The Bull Case

For the discerning value investor, BTX offers compelling reasons to buy. With an impressive operating margin of 87.75% and a robust ROIC of 3.85%, the company demonstrates strong capital efficiency. The FCF yield of 0.92% and a debt-free balance sheet further enhance its appeal, indicating solid cash flow management. These metrics suggest a company with significant pricing power and operational prowess.

The Bear Case

Despite its strengths, BTX faces structural risks that cannot be ignored. The Price/Sales ratio of 23.38 is alarmingly high, suggesting the stock is priced for perfection. Its current ratio of 0.13 indicates potential liquidity issues, raising concerns about short-term financial health. Additionally, the stock's proximity to its 52-week high suggests it may be technically overextended, warranting caution for potential investors.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

N/A

Average Analyst Price Target

N/A

Institutional Ownership %

1-Year Beta

1.34

Insider Buying % (6 Mo)

Distance to 52-Week High

0.00%

Distance to 52-Week Low

33.08%

EARNINGS SURPRISE %

N/A

50-DAY SMA

$7.63

200-DAY SMA

$6.98

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.